Clinical Trial

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Study acronym: SEATTLE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine. Thus, SEATTLE will provide real-world evidence complementary to pivotal studies.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-07-13; most recent amendment 2026-01-12.
Status change: Recruiting → Active, Not Recruiting 2026-01-12
Trial Details
NCT Number NCT05954780
Lead Sponsor iOMEDICO AG
Collaborators: Menarini Group, Climedo Health GmbH
Conditions Multiple Myeloma
Enrollment 75 participants
Start Date 2023-06-28
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-14